1998
Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines
Graham B, McElrath M, Connor R, Schwartz D, Gorse G, Keefer M, Mulligan M, Matthews T, Wolinsky S, Montefiori D, Vermund S, Lambert J, Corey L, Belshe R, Dolin R, Wright P, Korber B, Wolff M, Fast P, Group A. Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines. The Journal Of Infectious Diseases 1998, 177: 310-309. PMID: 9466516, DOI: 10.1086/514209.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS VaccinesAmino Acid SequenceCD4 Lymphocyte CountFemaleHIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHIV-1HumansImmunity, ActiveIncidenceMaleMiddle AgedMolecular Sequence DataNeutralization TestsPeptide FragmentsRisk-TakingSequence AnalysisSubstance Abuse, IntravenousViral LoadConceptsHIV-1 infectionHuman immunodeficiency virus type 1 (HIV-1) infectionVirus type 1 infectionCandidate AIDS vaccinesType 1 infectionAIDS vaccinePhase IHigh-risk sexual exposureVaccine-induced immune responsesComplete immunization scheduleEarly clinical courseCD4 lymphocyte countIntravenous drug useV3 loop amino acid sequencesUninfected subjectsVaccine recipientsLymphocyte countClinical courseImmunization scheduleSexual exposureVirus loadImmune responseControl groupDrug useInfection
1994
NIH conference. HIV vaccine development: a progress report.
Hoth DF, Bolognesi DP, Corey L, Vermund SH. NIH conference. HIV vaccine development: a progress report. Annals Of Internal Medicine 1994, 121: 603-11. PMID: 8085693, DOI: 10.7326/0003-4819-121-8-199410150-00008.Peer-Reviewed Original ResearchConceptsVaccine candidatesAnimal modelsHuman immunodeficiency virus (HIV) infectionCytotoxic T cell responsesLarge-scale efficacy trialsInnovative vaccine candidatesImmunodeficiency virus infectionT cell responsesCorrelates of immunityEffective preventive vaccineProtective immune responseDiversity of HIVHIV vaccine researchHuman phase IPromising vaccine candidateUseful animal modelPreventive vaccineEfficacy trialsVirus infectionImmune responseVaccine researchSuch trialsPhase ITrialsHIV